nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—CALM1—type 2 diabetes mellitus	0.301	0.828	CbGaD
Loperamide—CYP3A4—type 2 diabetes mellitus	0.0626	0.172	CbGaD
Loperamide—CYP2C8—Sitagliptin—type 2 diabetes mellitus	0.0276	0.0834	CbGbCtD
Loperamide—CYP2C8—Repaglinide—type 2 diabetes mellitus	0.0221	0.0667	CbGbCtD
Loperamide—ABCB1—Linagliptin—type 2 diabetes mellitus	0.021	0.0633	CbGbCtD
Loperamide—CYP2C8—Pioglitazone—type 2 diabetes mellitus	0.02	0.0603	CbGbCtD
Loperamide—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0187	0.0564	CbGbCtD
Loperamide—CYP2C8—Rosiglitazone—type 2 diabetes mellitus	0.0184	0.0556	CbGbCtD
Loperamide—CYP2C8—Tolbutamide—type 2 diabetes mellitus	0.0178	0.0537	CbGbCtD
Loperamide—CYP2C8—Irbesartan—type 2 diabetes mellitus	0.0145	0.0438	CbGbCtD
Loperamide—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.0135	0.0408	CbGbCtD
Loperamide—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.0127	0.0384	CbGbCtD
Loperamide—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0126	0.0379	CbGbCtD
Loperamide—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.0118	0.0355	CbGbCtD
Loperamide—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0112	0.0338	CbGbCtD
Loperamide—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0103	0.0309	CbGbCtD
Loperamide—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.00966	0.0291	CbGbCtD
Loperamide—CYP2C8—Losartan—type 2 diabetes mellitus	0.00936	0.0282	CbGbCtD
Loperamide—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.00929	0.028	CbGbCtD
Loperamide—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.00926	0.0279	CbGbCtD
Loperamide—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00896	0.027	CbGbCtD
Loperamide—POMC—sympathetic nervous system—type 2 diabetes mellitus	0.00858	0.136	CbGeAlD
Loperamide—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.0081	0.0244	CbGbCtD
Loperamide—POMC—brown adipose tissue—type 2 diabetes mellitus	0.00742	0.117	CbGeAlD
Loperamide—ABCB1—Glyburide—type 2 diabetes mellitus	0.00692	0.0209	CbGbCtD
Loperamide—ABCB1—Losartan—type 2 diabetes mellitus	0.00633	0.0191	CbGbCtD
Loperamide—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00614	0.0185	CbGbCtD
Loperamide—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00589	0.0178	CbGbCtD
Loperamide—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00589	0.0178	CbGbCtD
Loperamide—POMC—autonomic nervous system—type 2 diabetes mellitus	0.00577	0.0911	CbGeAlD
Loperamide—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00557	0.0168	CbGbCtD
Loperamide—POMC—peripheral nervous system—type 2 diabetes mellitus	0.00416	0.0657	CbGeAlD
Loperamide—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00415	0.0125	CbGbCtD
Loperamide—CYP3A4—Losartan—type 2 diabetes mellitus	0.00379	0.0114	CbGbCtD
Loperamide—POMC—nerve—type 2 diabetes mellitus	0.00324	0.0513	CbGeAlD
Loperamide—CACNA1A—nerve—type 2 diabetes mellitus	0.0031	0.0489	CbGeAlD
Loperamide—CALM1—sympathetic nervous system—type 2 diabetes mellitus	0.00233	0.0369	CbGeAlD
Loperamide—CALM1—autonomic nervous system—type 2 diabetes mellitus	0.00157	0.0248	CbGeAlD
Loperamide—CACNA1A—islet of Langerhans—type 2 diabetes mellitus	0.0015	0.0237	CbGeAlD
Loperamide—OPRM1—nerve—type 2 diabetes mellitus	0.00122	0.0193	CbGeAlD
Loperamide—CALM2—peripheral nervous system—type 2 diabetes mellitus	0.00114	0.018	CbGeAlD
Loperamide—POMC—cardiovascular system—type 2 diabetes mellitus	0.00114	0.018	CbGeAlD
Loperamide—CALM1—peripheral nervous system—type 2 diabetes mellitus	0.00113	0.0179	CbGeAlD
Loperamide—POMC—kidney—type 2 diabetes mellitus	0.00111	0.0176	CbGeAlD
Loperamide—POMC—pancreas—type 2 diabetes mellitus	0.0011	0.0175	CbGeAlD
Loperamide—POMC—adipose tissue—type 2 diabetes mellitus	0.001	0.0158	CbGeAlD
Loperamide—CALM2—artery—type 2 diabetes mellitus	0.000893	0.0141	CbGeAlD
Loperamide—CALM1—artery—type 2 diabetes mellitus	0.000889	0.014	CbGeAlD
Loperamide—CALM2—nerve—type 2 diabetes mellitus	0.000886	0.014	CbGeAlD
Loperamide—CALM1—nerve—type 2 diabetes mellitus	0.000882	0.0139	CbGeAlD
Loperamide—CALM2—endothelium—type 2 diabetes mellitus	0.000754	0.0119	CbGeAlD
Loperamide—CALM1—endothelium—type 2 diabetes mellitus	0.000751	0.0119	CbGeAlD
Loperamide—POMC—liver—type 2 diabetes mellitus	0.000703	0.0111	CbGeAlD
Loperamide—OPRD1—kidney—type 2 diabetes mellitus	0.000613	0.00969	CbGeAlD
Loperamide—CALM3—islet of Langerhans—type 2 diabetes mellitus	0.000546	0.00864	CbGeAlD
Loperamide—CALM3—retina—type 2 diabetes mellitus	0.000467	0.00738	CbGeAlD
Loperamide—CALM3—nephron tubule—type 2 diabetes mellitus	0.00044	0.00695	CbGeAlD
Loperamide—CALM2—islet of Langerhans—type 2 diabetes mellitus	0.000429	0.00678	CbGeAlD
Loperamide—CALM1—islet of Langerhans—type 2 diabetes mellitus	0.000427	0.00675	CbGeAlD
Loperamide—CALM3—pancreas—type 2 diabetes mellitus	0.000384	0.00607	CbGeAlD
Loperamide—CALM3—cortex of kidney—type 2 diabetes mellitus	0.000377	0.00595	CbGeAlD
Loperamide—CALM2—retina—type 2 diabetes mellitus	0.000367	0.0058	CbGeAlD
Loperamide—CALM1—retina—type 2 diabetes mellitus	0.000365	0.00577	CbGeAlD
Loperamide—CALM3—adipose tissue—type 2 diabetes mellitus	0.000348	0.00551	CbGeAlD
Loperamide—CALM2—nephron tubule—type 2 diabetes mellitus	0.000345	0.00546	CbGeAlD
Loperamide—CALM1—nephron tubule—type 2 diabetes mellitus	0.000344	0.00544	CbGeAlD
Loperamide—CALM2—cardiovascular system—type 2 diabetes mellitus	0.00031	0.0049	CbGeAlD
Loperamide—CALM1—cardiovascular system—type 2 diabetes mellitus	0.000309	0.00488	CbGeAlD
Loperamide—CALM2—kidney—type 2 diabetes mellitus	0.000304	0.0048	CbGeAlD
Loperamide—CALM1—kidney—type 2 diabetes mellitus	0.000302	0.00478	CbGeAlD
Loperamide—CALM2—pancreas—type 2 diabetes mellitus	0.000302	0.00477	CbGeAlD
Loperamide—CALM1—pancreas—type 2 diabetes mellitus	0.0003	0.00475	CbGeAlD
Loperamide—CALM2—cortex of kidney—type 2 diabetes mellitus	0.000296	0.00467	CbGeAlD
Loperamide—CALM1—cortex of kidney—type 2 diabetes mellitus	0.000294	0.00465	CbGeAlD
Loperamide—Clotrimazole—CYP11A1—type 2 diabetes mellitus	0.000281	0.135	CrCbGaD
Loperamide—CALM2—adipose tissue—type 2 diabetes mellitus	0.000274	0.00432	CbGeAlD
Loperamide—CALM1—adipose tissue—type 2 diabetes mellitus	0.000272	0.00431	CbGeAlD
Loperamide—CYP2B6—nephron tubule—type 2 diabetes mellitus	0.000257	0.00406	CbGeAlD
Loperamide—CYP2C8—kidney—type 2 diabetes mellitus	0.000252	0.00398	CbGeAlD
Loperamide—CALM3—liver—type 2 diabetes mellitus	0.000244	0.00386	CbGeAlD
Loperamide—CYP2B6—cardiovascular system—type 2 diabetes mellitus	0.000231	0.00365	CbGeAlD
Loperamide—CYP2B6—kidney—type 2 diabetes mellitus	0.000226	0.00357	CbGeAlD
Loperamide—Meclizine—CYP1A2—type 2 diabetes mellitus	0.000205	0.098	CrCbGaD
Loperamide—Loss of consciousness—Gliclazide—type 2 diabetes mellitus	0.000192	0.00163	CcSEcCtD
Loperamide—CALM2—liver—type 2 diabetes mellitus	0.000192	0.00303	CbGeAlD
Loperamide—Urticaria—Glimepiride—type 2 diabetes mellitus	0.000191	0.00162	CcSEcCtD
Loperamide—Dyspepsia—Bromocriptine—type 2 diabetes mellitus	0.000191	0.00162	CcSEcCtD
Loperamide—CALM1—liver—type 2 diabetes mellitus	0.000191	0.00302	CbGeAlD
Loperamide—Urticaria—Sitagliptin—type 2 diabetes mellitus	0.000191	0.00162	CcSEcCtD
Loperamide—Abdominal pain—Glimepiride—type 2 diabetes mellitus	0.00019	0.00161	CcSEcCtD
Loperamide—Hypersensitivity—Glipizide—type 2 diabetes mellitus	0.00019	0.00161	CcSEcCtD
Loperamide—Abdominal pain—Sitagliptin—type 2 diabetes mellitus	0.00019	0.00161	CcSEcCtD
Loperamide—Immune system disorder—Metformin—type 2 diabetes mellitus	0.00019	0.00161	CcSEcCtD
Loperamide—Gastrointestinal disorder—Bromocriptine—type 2 diabetes mellitus	0.000188	0.00159	CcSEcCtD
Loperamide—Fatigue—Bromocriptine—type 2 diabetes mellitus	0.000187	0.00159	CcSEcCtD
Loperamide—Rash—Rosiglitazone—type 2 diabetes mellitus	0.000186	0.00157	CcSEcCtD
Loperamide—Constipation—Bromocriptine—type 2 diabetes mellitus	0.000186	0.00157	CcSEcCtD
Loperamide—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	0.000186	0.00157	CcSEcCtD
Loperamide—Nausea—Repaglinide—type 2 diabetes mellitus	0.000185	0.00157	CcSEcCtD
Loperamide—Asthenia—Glipizide—type 2 diabetes mellitus	0.000185	0.00157	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Gliclazide—type 2 diabetes mellitus	0.000185	0.00156	CcSEcCtD
Loperamide—Headache—Rosiglitazone—type 2 diabetes mellitus	0.000185	0.00156	CcSEcCtD
Loperamide—Discomfort—Gliclazide—type 2 diabetes mellitus	0.000184	0.00156	CcSEcCtD
Loperamide—Angioedema—Valsartan—type 2 diabetes mellitus	0.000183	0.00155	CcSEcCtD
Loperamide—Pruritus—Glipizide—type 2 diabetes mellitus	0.000183	0.00155	CcSEcCtD
Loperamide—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	0.000182	0.00154	CcSEcCtD
Loperamide—Dry mouth—Gliclazide—type 2 diabetes mellitus	0.000182	0.00154	CcSEcCtD
Loperamide—Angioedema—Orlistat—type 2 diabetes mellitus	0.000181	0.00154	CcSEcCtD
Loperamide—Flatulence—Metformin—type 2 diabetes mellitus	0.00018	0.00153	CcSEcCtD
Loperamide—Immune system disorder—Irbesartan—type 2 diabetes mellitus	0.000179	0.00152	CcSEcCtD
Loperamide—Gastrointestinal pain—Bromocriptine—type 2 diabetes mellitus	0.000178	0.0015	CcSEcCtD
Loperamide—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	0.000177	0.0015	CcSEcCtD
Loperamide—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.000177	0.0015	CcSEcCtD
Loperamide—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.000177	0.0015	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Ramipril—type 2 diabetes mellitus	0.000177	0.0015	CcSEcCtD
Loperamide—Diarrhoea—Glipizide—type 2 diabetes mellitus	0.000177	0.0015	CcSEcCtD
Loperamide—Loss of consciousness—Valsartan—type 2 diabetes mellitus	0.000177	0.00149	CcSEcCtD
Loperamide—Erythema multiforme—Losartan—type 2 diabetes mellitus	0.000176	0.00149	CcSEcCtD
Loperamide—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000175	0.00148	CcSEcCtD
Loperamide—Nervous system disorder—Gliclazide—type 2 diabetes mellitus	0.000175	0.00148	CcSEcCtD
Loperamide—Dyspepsia—Glyburide—type 2 diabetes mellitus	0.000175	0.00148	CcSEcCtD
Loperamide—Skin disorder—Gliclazide—type 2 diabetes mellitus	0.000173	0.00147	CcSEcCtD
Loperamide—Asthenia—Glimepiride—type 2 diabetes mellitus	0.000173	0.00146	CcSEcCtD
Loperamide—Urticaria—Bromocriptine—type 2 diabetes mellitus	0.000173	0.00146	CcSEcCtD
Loperamide—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000172	0.00146	CcSEcCtD
Loperamide—Abdominal pain—Bromocriptine—type 2 diabetes mellitus	0.000172	0.00145	CcSEcCtD
Loperamide—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.000172	0.00145	CcSEcCtD
Loperamide—Dizziness—Glipizide—type 2 diabetes mellitus	0.000171	0.00145	CcSEcCtD
Loperamide—ABCB1—islet of Langerhans—type 2 diabetes mellitus	0.00017	0.00269	CbGeAlD
Loperamide—Pruritus—Glimepiride—type 2 diabetes mellitus	0.00017	0.00144	CcSEcCtD
Loperamide—CYP3A4—kidney—type 2 diabetes mellitus	0.00017	0.00269	CbGeAlD
Loperamide—Flatulence—Irbesartan—type 2 diabetes mellitus	0.00017	0.00144	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	0.00017	0.00144	CcSEcCtD
Loperamide—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.000169	0.00143	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	0.000168	0.00142	CcSEcCtD
Loperamide—CYP2D6—kidney—type 2 diabetes mellitus	0.000168	0.00265	CbGeAlD
Loperamide—Dry mouth—Valsartan—type 2 diabetes mellitus	0.000167	0.00142	CcSEcCtD
Loperamide—Discomfort—Orlistat—type 2 diabetes mellitus	0.000167	0.00141	CcSEcCtD
Loperamide—Dry mouth—Orlistat—type 2 diabetes mellitus	0.000165	0.0014	CcSEcCtD
Loperamide—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.000165	0.0014	CcSEcCtD
Loperamide—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.000164	0.00139	CcSEcCtD
Loperamide—Vomiting—Glipizide—type 2 diabetes mellitus	0.000164	0.00139	CcSEcCtD
Loperamide—Anaphylactic shock—Valsartan—type 2 diabetes mellitus	0.000164	0.00139	CcSEcCtD
Loperamide—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000164	0.00138	CcSEcCtD
Loperamide—Rash—Glipizide—type 2 diabetes mellitus	0.000163	0.00138	CcSEcCtD
Loperamide—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000163	0.00138	CcSEcCtD
Loperamide—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	0.000162	0.00138	CcSEcCtD
Loperamide—Anaphylactic shock—Orlistat—type 2 diabetes mellitus	0.000162	0.00137	CcSEcCtD
Loperamide—Headache—Glipizide—type 2 diabetes mellitus	0.000162	0.00137	CcSEcCtD
Loperamide—Loss of consciousness—Metformin—type 2 diabetes mellitus	0.000161	0.00136	CcSEcCtD
Loperamide—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.000161	0.00136	CcSEcCtD
Loperamide—Flatulence—Losartan—type 2 diabetes mellitus	0.00016	0.00136	CcSEcCtD
Loperamide—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000159	0.00135	CcSEcCtD
Loperamide—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000159	0.00135	CcSEcCtD
Loperamide—CYP2C8—liver—type 2 diabetes mellitus	0.000159	0.00251	CbGeAlD
Loperamide—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000159	0.00134	CcSEcCtD
Loperamide—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000159	0.00134	CcSEcCtD
Loperamide—Somnolence—Gliclazide—type 2 diabetes mellitus	0.000159	0.00134	CcSEcCtD
Loperamide—Urticaria—Glyburide—type 2 diabetes mellitus	0.000158	0.00134	CcSEcCtD
Loperamide—Angioedema—Irbesartan—type 2 diabetes mellitus	0.000158	0.00134	CcSEcCtD
Loperamide—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000157	0.00133	CcSEcCtD
Loperamide—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.000157	0.00133	CcSEcCtD
Loperamide—Dyspepsia—Gliclazide—type 2 diabetes mellitus	0.000157	0.00133	CcSEcCtD
Loperamide—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000156	0.00132	CcSEcCtD
Loperamide—Headache—Pioglitazone—type 2 diabetes mellitus	0.000155	0.00131	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000155	0.00131	CcSEcCtD
Loperamide—Clotrimazole—ABCC2—type 2 diabetes mellitus	0.000154	0.0739	CrCbGaD
Loperamide—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000154	0.0013	CcSEcCtD
Loperamide—Discomfort—Metformin—type 2 diabetes mellitus	0.000154	0.0013	CcSEcCtD
Loperamide—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000154	0.0013	CcSEcCtD
Loperamide—Nausea—Glipizide—type 2 diabetes mellitus	0.000153	0.0013	CcSEcCtD
Loperamide—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000153	0.0013	CcSEcCtD
Loperamide—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000153	0.00129	CcSEcCtD
Loperamide—Constipation—Gliclazide—type 2 diabetes mellitus	0.000153	0.00129	CcSEcCtD
Loperamide—Toremifene—CYP1A2—type 2 diabetes mellitus	0.000153	0.0731	CrCbGaD
Loperamide—Rash—Glimepiride—type 2 diabetes mellitus	0.000152	0.00129	CcSEcCtD
Loperamide—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000152	0.00129	CcSEcCtD
Loperamide—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	0.000152	0.00128	CcSEcCtD
Loperamide—Rash—Sitagliptin—type 2 diabetes mellitus	0.000151	0.00128	CcSEcCtD
Loperamide—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000151	0.00128	CcSEcCtD
Loperamide—Erythema multiforme—Ramipril—type 2 diabetes mellitus	0.000151	0.00128	CcSEcCtD
Loperamide—Headache—Glimepiride—type 2 diabetes mellitus	0.000151	0.00128	CcSEcCtD
Loperamide—Headache—Sitagliptin—type 2 diabetes mellitus	0.00015	0.00127	CcSEcCtD
Loperamide—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000149	0.00126	CcSEcCtD
Loperamide—Angioedema—Losartan—type 2 diabetes mellitus	0.000148	0.00126	CcSEcCtD
Loperamide—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000146	0.00124	CcSEcCtD
Loperamide—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000146	0.00124	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000146	0.00124	CcSEcCtD
Loperamide—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000146	0.00124	CcSEcCtD
Loperamide—ABCB1—retina—type 2 diabetes mellitus	0.000146	0.0023	CbGeAlD
Loperamide—Somnolence—Valsartan—type 2 diabetes mellitus	0.000146	0.00123	CcSEcCtD
Loperamide—Discomfort—Irbesartan—type 2 diabetes mellitus	0.000145	0.00123	CcSEcCtD
Loperamide—Skin disorder—Metformin—type 2 diabetes mellitus	0.000145	0.00123	CcSEcCtD
Loperamide—Immune system disorder—Ramipril—type 2 diabetes mellitus	0.000145	0.00122	CcSEcCtD
Loperamide—Dyspepsia—Valsartan—type 2 diabetes mellitus	0.000144	0.00122	CcSEcCtD
Loperamide—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000144	0.00122	CcSEcCtD
Loperamide—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000144	0.00122	CcSEcCtD
Loperamide—Nausea—Glimepiride—type 2 diabetes mellitus	0.000143	0.00121	CcSEcCtD
Loperamide—Loss of consciousness—Losartan—type 2 diabetes mellitus	0.000143	0.00121	CcSEcCtD
Loperamide—CYP2B6—liver—type 2 diabetes mellitus	0.000143	0.00225	CbGeAlD
Loperamide—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000143	0.00121	CcSEcCtD
Loperamide—Dyspepsia—Orlistat—type 2 diabetes mellitus	0.000143	0.00121	CcSEcCtD
Loperamide—Asthenia—Glyburide—type 2 diabetes mellitus	0.000143	0.00121	CcSEcCtD
Loperamide—Urticaria—Gliclazide—type 2 diabetes mellitus	0.000142	0.0012	CcSEcCtD
Loperamide—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000141	0.0012	CcSEcCtD
Loperamide—Fatigue—Valsartan—type 2 diabetes mellitus	0.000141	0.0012	CcSEcCtD
Loperamide—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000141	0.00119	CcSEcCtD
Loperamide—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.000141	0.00119	CcSEcCtD
Loperamide—Pruritus—Glyburide—type 2 diabetes mellitus	0.000141	0.00119	CcSEcCtD
Loperamide—Constipation—Valsartan—type 2 diabetes mellitus	0.00014	0.00119	CcSEcCtD
Loperamide—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.00014	0.00118	CcSEcCtD
Loperamide—Fatigue—Orlistat—type 2 diabetes mellitus	0.00014	0.00118	CcSEcCtD
Loperamide—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000138	0.00117	CcSEcCtD
Loperamide—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000138	0.00117	CcSEcCtD
Loperamide—ABCB1—nephron tubule—type 2 diabetes mellitus	0.000137	0.00217	CbGeAlD
Loperamide—Rash—Bromocriptine—type 2 diabetes mellitus	0.000137	0.00116	CcSEcCtD
Loperamide—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000137	0.00116	CcSEcCtD
Loperamide—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000137	0.00116	CcSEcCtD
Loperamide—Discomfort—Losartan—type 2 diabetes mellitus	0.000137	0.00116	CcSEcCtD
Loperamide—Headache—Bromocriptine—type 2 diabetes mellitus	0.000136	0.00115	CcSEcCtD
Loperamide—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000136	0.00115	CcSEcCtD
Loperamide—Dry mouth—Losartan—type 2 diabetes mellitus	0.000135	0.00115	CcSEcCtD
Loperamide—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.000134	0.00113	CcSEcCtD
Loperamide—Somnolence—Metformin—type 2 diabetes mellitus	0.000133	0.00112	CcSEcCtD
Loperamide—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.000133	0.00112	CcSEcCtD
Loperamide—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.000132	0.00112	CcSEcCtD
Loperamide—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.000131	0.00111	CcSEcCtD
Loperamide—Dyspepsia—Metformin—type 2 diabetes mellitus	0.000131	0.00111	CcSEcCtD
Loperamide—Urticaria—Valsartan—type 2 diabetes mellitus	0.00013	0.0011	CcSEcCtD
Loperamide—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.00013	0.0011	CcSEcCtD
Loperamide—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.00013	0.0011	CcSEcCtD
Loperamide—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000129	0.00109	CcSEcCtD
Loperamide—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000129	0.00109	CcSEcCtD
Loperamide—Fatigue—Metformin—type 2 diabetes mellitus	0.000129	0.00109	CcSEcCtD
Loperamide—Urticaria—Orlistat—type 2 diabetes mellitus	0.000129	0.00109	CcSEcCtD
Loperamide—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.000128	0.00108	CcSEcCtD
Loperamide—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000128	0.00108	CcSEcCtD
Loperamide—Constipation—Metformin—type 2 diabetes mellitus	0.000128	0.00108	CcSEcCtD
Loperamide—Clemastine—CYP3A4—type 2 diabetes mellitus	0.000127	0.061	CrCbGaD
Loperamide—Angioedema—Ramipril—type 2 diabetes mellitus	0.000127	0.00108	CcSEcCtD
Loperamide—Vomiting—Glyburide—type 2 diabetes mellitus	0.000126	0.00107	CcSEcCtD
Loperamide—Pruritus—Gliclazide—type 2 diabetes mellitus	0.000126	0.00107	CcSEcCtD
Loperamide—Rash—Glyburide—type 2 diabetes mellitus	0.000125	0.00106	CcSEcCtD
Loperamide—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000125	0.00106	CcSEcCtD
Loperamide—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000125	0.00106	CcSEcCtD
Loperamide—Headache—Glyburide—type 2 diabetes mellitus	0.000124	0.00105	CcSEcCtD
Loperamide—Dyspepsia—Irbesartan—type 2 diabetes mellitus	0.000124	0.00105	CcSEcCtD
Loperamide—ABCB1—cardiovascular system—type 2 diabetes mellitus	0.000123	0.00195	CbGeAlD
Loperamide—Loss of consciousness—Ramipril—type 2 diabetes mellitus	0.000122	0.00104	CcSEcCtD
Loperamide—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000122	0.00103	CcSEcCtD
Loperamide—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.000122	0.00103	CcSEcCtD
Loperamide—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000122	0.00103	CcSEcCtD
Loperamide—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000121	0.00103	CcSEcCtD
Loperamide—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.000121	0.00102	CcSEcCtD
Loperamide—ABCB1—kidney—type 2 diabetes mellitus	0.000121	0.00191	CbGeAlD
Loperamide—Constipation—Irbesartan—type 2 diabetes mellitus	0.00012	0.00102	CcSEcCtD
Loperamide—ABCB1—pancreas—type 2 diabetes mellitus	0.00012	0.00189	CbGeAlD
Loperamide—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000119	0.00101	CcSEcCtD
Loperamide—Urticaria—Metformin—type 2 diabetes mellitus	0.000119	0.001	CcSEcCtD
Loperamide—Nausea—Glyburide—type 2 diabetes mellitus	0.000118	0.000999	CcSEcCtD
Loperamide—Abdominal pain—Metformin—type 2 diabetes mellitus	0.000118	0.000999	CcSEcCtD
Loperamide—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000118	0.000999	CcSEcCtD
Loperamide—Somnolence—Losartan—type 2 diabetes mellitus	0.000118	0.000998	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000118	0.000997	CcSEcCtD
Loperamide—Asthenia—Valsartan—type 2 diabetes mellitus	0.000118	0.000996	CcSEcCtD
Loperamide—ABCB1—cortex of kidney—type 2 diabetes mellitus	0.000117	0.00186	CbGeAlD
Loperamide—Discomfort—Ramipril—type 2 diabetes mellitus	0.000117	0.000992	CcSEcCtD
Loperamide—Dyspepsia—Losartan—type 2 diabetes mellitus	0.000117	0.000988	CcSEcCtD
Loperamide—Asthenia—Orlistat—type 2 diabetes mellitus	0.000116	0.000984	CcSEcCtD
Loperamide—Pruritus—Valsartan—type 2 diabetes mellitus	0.000116	0.000982	CcSEcCtD
Loperamide—Dry mouth—Ramipril—type 2 diabetes mellitus	0.000116	0.000982	CcSEcCtD
Loperamide—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	0.000115	0.000975	CcSEcCtD
Loperamide—Pruritus—Orlistat—type 2 diabetes mellitus	0.000115	0.00097	CcSEcCtD
Loperamide—Fatigue—Losartan—type 2 diabetes mellitus	0.000114	0.000968	CcSEcCtD
Loperamide—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	0.000114	0.000962	CcSEcCtD
Loperamide—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000113	0.00096	CcSEcCtD
Loperamide—Constipation—Losartan—type 2 diabetes mellitus	0.000113	0.00096	CcSEcCtD
Loperamide—Rash—Gliclazide—type 2 diabetes mellitus	0.000112	0.000952	CcSEcCtD
Loperamide—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000112	0.000952	CcSEcCtD
Loperamide—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000112	0.00095	CcSEcCtD
Loperamide—Urticaria—Irbesartan—type 2 diabetes mellitus	0.000112	0.000948	CcSEcCtD
Loperamide—Headache—Gliclazide—type 2 diabetes mellitus	0.000112	0.000946	CcSEcCtD
Loperamide—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.000111	0.000944	CcSEcCtD
Loperamide—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.000111	0.000943	CcSEcCtD
Loperamide—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000111	0.000938	CcSEcCtD
Loperamide—Skin disorder—Ramipril—type 2 diabetes mellitus	0.00011	0.000935	CcSEcCtD
Loperamide—ABCB1—adipose tissue—type 2 diabetes mellitus	0.000109	0.00172	CbGeAlD
Loperamide—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	0.000108	0.000918	CcSEcCtD
Loperamide—Dizziness—Valsartan—type 2 diabetes mellitus	0.000108	0.000918	CcSEcCtD
Loperamide—Clotrimazole—CYP2E1—type 2 diabetes mellitus	0.000108	0.0519	CrCbGaD
Loperamide—CYP3A4—liver—type 2 diabetes mellitus	0.000108	0.0017	CbGeAlD
Loperamide—Dizziness—Orlistat—type 2 diabetes mellitus	0.000107	0.000907	CcSEcCtD
Loperamide—Asthenia—Metformin—type 2 diabetes mellitus	0.000107	0.000907	CcSEcCtD
Loperamide—CYP2D6—liver—type 2 diabetes mellitus	0.000106	0.00168	CbGeAlD
Loperamide—Nausea—Gliclazide—type 2 diabetes mellitus	0.000106	0.000897	CcSEcCtD
Loperamide—Pruritus—Metformin—type 2 diabetes mellitus	0.000106	0.000894	CcSEcCtD
Loperamide—Urticaria—Losartan—type 2 diabetes mellitus	0.000105	0.000892	CcSEcCtD
Loperamide—Abdominal pain—Losartan—type 2 diabetes mellitus	0.000105	0.000887	CcSEcCtD
Loperamide—Vomiting—Valsartan—type 2 diabetes mellitus	0.000104	0.000882	CcSEcCtD
Loperamide—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.000104	0.000879	CcSEcCtD
Loperamide—Rash—Valsartan—type 2 diabetes mellitus	0.000103	0.000875	CcSEcCtD
Loperamide—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000103	0.000874	CcSEcCtD
Loperamide—Clotrimazole—CYP1A2—type 2 diabetes mellitus	0.000103	0.0494	CrCbGaD
Loperamide—Vomiting—Orlistat—type 2 diabetes mellitus	0.000103	0.000872	CcSEcCtD
Loperamide—Headache—Valsartan—type 2 diabetes mellitus	0.000103	0.000869	CcSEcCtD
Loperamide—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000102	0.000865	CcSEcCtD
Loperamide—Rash—Orlistat—type 2 diabetes mellitus	0.000102	0.000865	CcSEcCtD
Loperamide—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000102	0.000864	CcSEcCtD
Loperamide—Headache—Orlistat—type 2 diabetes mellitus	0.000101	0.000859	CcSEcCtD
Loperamide—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000101	0.000856	CcSEcCtD
Loperamide—Somnolence—Ramipril—type 2 diabetes mellitus	0.000101	0.000856	CcSEcCtD
Loperamide—Toremifene—CYP3A4—type 2 diabetes mellitus	0.000101	0.0484	CrCbGaD
Loperamide—Dyspepsia—Ramipril—type 2 diabetes mellitus	0.0001	0.000847	CcSEcCtD
Loperamide—Pruritus—Irbesartan—type 2 diabetes mellitus	9.97e-05	0.000844	CcSEcCtD
Loperamide—Dizziness—Metformin—type 2 diabetes mellitus	9.87e-05	0.000836	CcSEcCtD
Loperamide—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	9.81e-05	0.000831	CcSEcCtD
Loperamide—Fatigue—Ramipril—type 2 diabetes mellitus	9.8e-05	0.00083	CcSEcCtD
Loperamide—Hypersensitivity—Losartan—type 2 diabetes mellitus	9.77e-05	0.000827	CcSEcCtD
Loperamide—Nausea—Valsartan—type 2 diabetes mellitus	9.74e-05	0.000824	CcSEcCtD
Loperamide—Constipation—Ramipril—type 2 diabetes mellitus	9.72e-05	0.000823	CcSEcCtD
Loperamide—Diarrhoea—Irbesartan—type 2 diabetes mellitus	9.64e-05	0.000816	CcSEcCtD
Loperamide—Nausea—Orlistat—type 2 diabetes mellitus	9.62e-05	0.000815	CcSEcCtD
Loperamide—Asthenia—Losartan—type 2 diabetes mellitus	9.51e-05	0.000805	CcSEcCtD
Loperamide—Vomiting—Metformin—type 2 diabetes mellitus	9.49e-05	0.000804	CcSEcCtD
Loperamide—Rash—Metformin—type 2 diabetes mellitus	9.41e-05	0.000797	CcSEcCtD
Loperamide—Dermatitis—Metformin—type 2 diabetes mellitus	9.4e-05	0.000796	CcSEcCtD
Loperamide—Pruritus—Losartan—type 2 diabetes mellitus	9.38e-05	0.000794	CcSEcCtD
Loperamide—Headache—Metformin—type 2 diabetes mellitus	9.35e-05	0.000792	CcSEcCtD
Loperamide—Dizziness—Irbesartan—type 2 diabetes mellitus	9.31e-05	0.000789	CcSEcCtD
Loperamide—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	9.29e-05	0.000787	CcSEcCtD
Loperamide—Haloperidol—CYP1A2—type 2 diabetes mellitus	9.28e-05	0.0444	CrCbGaD
Loperamide—Tamoxifen—ABCC2—type 2 diabetes mellitus	9.13e-05	0.0437	CrCbGaD
Loperamide—Darifenacin—CYP3A4—type 2 diabetes mellitus	9.07e-05	0.0435	CrCbGaD
Loperamide—Diarrhoea—Losartan—type 2 diabetes mellitus	9.07e-05	0.000768	CcSEcCtD
Loperamide—Urticaria—Ramipril—type 2 diabetes mellitus	9.03e-05	0.000765	CcSEcCtD
Loperamide—Abdominal pain—Ramipril—type 2 diabetes mellitus	8.98e-05	0.000761	CcSEcCtD
Loperamide—Vomiting—Irbesartan—type 2 diabetes mellitus	8.96e-05	0.000758	CcSEcCtD
Loperamide—Rash—Irbesartan—type 2 diabetes mellitus	8.88e-05	0.000752	CcSEcCtD
Loperamide—Dermatitis—Irbesartan—type 2 diabetes mellitus	8.87e-05	0.000751	CcSEcCtD
Loperamide—Nausea—Metformin—type 2 diabetes mellitus	8.87e-05	0.000751	CcSEcCtD
Loperamide—Headache—Irbesartan—type 2 diabetes mellitus	8.82e-05	0.000747	CcSEcCtD
Loperamide—Dizziness—Losartan—type 2 diabetes mellitus	8.77e-05	0.000742	CcSEcCtD
Loperamide—Vomiting—Losartan—type 2 diabetes mellitus	8.43e-05	0.000714	CcSEcCtD
Loperamide—Hypersensitivity—Ramipril—type 2 diabetes mellitus	8.37e-05	0.000709	CcSEcCtD
Loperamide—Nausea—Irbesartan—type 2 diabetes mellitus	8.37e-05	0.000708	CcSEcCtD
Loperamide—Rash—Losartan—type 2 diabetes mellitus	8.36e-05	0.000708	CcSEcCtD
Loperamide—Dermatitis—Losartan—type 2 diabetes mellitus	8.35e-05	0.000707	CcSEcCtD
Loperamide—Headache—Losartan—type 2 diabetes mellitus	8.3e-05	0.000703	CcSEcCtD
Loperamide—Asthenia—Ramipril—type 2 diabetes mellitus	8.15e-05	0.000691	CcSEcCtD
Loperamide—Pruritus—Ramipril—type 2 diabetes mellitus	8.04e-05	0.000681	CcSEcCtD
Loperamide—Nausea—Losartan—type 2 diabetes mellitus	7.87e-05	0.000667	CcSEcCtD
Loperamide—Diarrhoea—Ramipril—type 2 diabetes mellitus	7.78e-05	0.000659	CcSEcCtD
Loperamide—ABCB1—liver—type 2 diabetes mellitus	7.63e-05	0.00121	CbGeAlD
Loperamide—Dizziness—Ramipril—type 2 diabetes mellitus	7.52e-05	0.000636	CcSEcCtD
Loperamide—Vomiting—Ramipril—type 2 diabetes mellitus	7.23e-05	0.000612	CcSEcCtD
Loperamide—Rash—Ramipril—type 2 diabetes mellitus	7.17e-05	0.000607	CcSEcCtD
Loperamide—Dermatitis—Ramipril—type 2 diabetes mellitus	7.16e-05	0.000606	CcSEcCtD
Loperamide—Headache—Ramipril—type 2 diabetes mellitus	7.12e-05	0.000603	CcSEcCtD
Loperamide—Levomethadyl Acetate—CYP3A4—type 2 diabetes mellitus	6.82e-05	0.0327	CrCbGaD
Loperamide—Clotrimazole—CYP3A4—type 2 diabetes mellitus	6.82e-05	0.0327	CrCbGaD
Loperamide—Nausea—Ramipril—type 2 diabetes mellitus	6.75e-05	0.000572	CcSEcCtD
Loperamide—Tamoxifen—CYP2E1—type 2 diabetes mellitus	6.4e-05	0.0307	CrCbGaD
Loperamide—Haloperidol—CYP3A4—type 2 diabetes mellitus	6.14e-05	0.0294	CrCbGaD
Loperamide—Tamoxifen—CYP1A2—type 2 diabetes mellitus	6.09e-05	0.0292	CrCbGaD
Loperamide—Methadone—CYP1A2—type 2 diabetes mellitus	6.04e-05	0.0289	CrCbGaD
Loperamide—Dextropropoxyphene—CYP3A4—type 2 diabetes mellitus	5.9e-05	0.0282	CrCbGaD
Loperamide—Fentanyl—CYP3A4—type 2 diabetes mellitus	5.83e-05	0.0279	CrCbGaD
Loperamide—Tamoxifen—CYP3A4—type 2 diabetes mellitus	4.03e-05	0.0193	CrCbGaD
Loperamide—Methadone—CYP3A4—type 2 diabetes mellitus	4e-05	0.0192	CrCbGaD
Loperamide—OPRK1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.61e-06	1.33e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—APOA1—type 2 diabetes mellitus	1.61e-06	1.32e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.61e-06	1.32e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	1.61e-06	1.32e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.6e-06	1.32e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.6e-06	1.31e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—INS—type 2 diabetes mellitus	1.6e-06	1.31e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.6e-06	1.31e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—AGT—type 2 diabetes mellitus	1.59e-06	1.31e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	1.59e-06	1.31e-05	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—AKT1—type 2 diabetes mellitus	1.59e-06	1.31e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	1.59e-06	1.3e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PPARG—type 2 diabetes mellitus	1.57e-06	1.3e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PPARG—type 2 diabetes mellitus	1.57e-06	1.3e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.57e-06	1.29e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—LEP—type 2 diabetes mellitus	1.56e-06	1.29e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—APOE—type 2 diabetes mellitus	1.56e-06	1.29e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	1.56e-06	1.28e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	1.55e-06	1.28e-05	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—IL6—type 2 diabetes mellitus	1.55e-06	1.27e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.55e-06	1.27e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.55e-06	1.27e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.54e-06	1.27e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.54e-06	1.27e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.54e-06	1.27e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—INS—type 2 diabetes mellitus	1.54e-06	1.27e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—INS—type 2 diabetes mellitus	1.54e-06	1.27e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—AGT—type 2 diabetes mellitus	1.54e-06	1.27e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—AGT—type 2 diabetes mellitus	1.54e-06	1.27e-05	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—AKT1—type 2 diabetes mellitus	1.54e-06	1.26e-05	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—AKT1—type 2 diabetes mellitus	1.54e-06	1.26e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	1.53e-06	1.26e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	1.53e-06	1.26e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	1.53e-06	1.26e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—PTGS2—type 2 diabetes mellitus	1.53e-06	1.26e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	1.52e-06	1.25e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.52e-06	1.25e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.52e-06	1.25e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	1.51e-06	1.24e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—APOE—type 2 diabetes mellitus	1.51e-06	1.24e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—APOE—type 2 diabetes mellitus	1.51e-06	1.24e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—LEP—type 2 diabetes mellitus	1.51e-06	1.24e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—LEP—type 2 diabetes mellitus	1.51e-06	1.24e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—ALB—type 2 diabetes mellitus	1.5e-06	1.24e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	1.5e-06	1.24e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.5e-06	1.23e-05	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—IL6—type 2 diabetes mellitus	1.5e-06	1.23e-05	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—IL6—type 2 diabetes mellitus	1.5e-06	1.23e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.49e-06	1.23e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.49e-06	1.23e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	1.49e-06	1.23e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	1.49e-06	1.23e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	1.49e-06	1.22e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.48e-06	1.22e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—PTGS2—type 2 diabetes mellitus	1.48e-06	1.22e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—PTGS2—type 2 diabetes mellitus	1.48e-06	1.22e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.47e-06	1.21e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.47e-06	1.21e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—ALB—type 2 diabetes mellitus	1.46e-06	1.2e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	1.46e-06	1.2e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.45e-06	1.19e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	1.45e-06	1.19e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—NOS3—type 2 diabetes mellitus	1.44e-06	1.18e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PIK3R1—type 2 diabetes mellitus	1.44e-06	1.18e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—NFKB1—type 2 diabetes mellitus	1.44e-06	1.18e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	1.43e-06	1.18e-05	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—AKT1—type 2 diabetes mellitus	1.43e-06	1.18e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.43e-06	1.17e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.43e-06	1.17e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	1.42e-06	1.17e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	1.42e-06	1.16e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PPARG—type 2 diabetes mellitus	1.42e-06	1.16e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—ALB—type 2 diabetes mellitus	1.42e-06	1.16e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—ALB—type 2 diabetes mellitus	1.42e-06	1.16e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	1.41e-06	1.16e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PIK3R1—type 2 diabetes mellitus	1.4e-06	1.15e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—NOS3—type 2 diabetes mellitus	1.4e-06	1.15e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	1.4e-06	1.15e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	1.4e-06	1.15e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.4e-06	1.15e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.39e-06	1.15e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—NFKB1—type 2 diabetes mellitus	1.39e-06	1.14e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—NFKB1—type 2 diabetes mellitus	1.39e-06	1.14e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—INS—type 2 diabetes mellitus	1.39e-06	1.14e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	1.38e-06	1.14e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	1.38e-06	1.14e-05	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—AKT1—type 2 diabetes mellitus	1.38e-06	1.14e-05	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—AKT1—type 2 diabetes mellitus	1.38e-06	1.14e-05	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—AKT1—type 2 diabetes mellitus	1.37e-06	1.13e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.36e-06	1.12e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	1.36e-06	1.12e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—NOS3—type 2 diabetes mellitus	1.35e-06	1.11e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PIK3R1—type 2 diabetes mellitus	1.35e-06	1.11e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—NOS3—type 2 diabetes mellitus	1.35e-06	1.11e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.35e-06	1.11e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.35e-06	1.11e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.35e-06	1.11e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—SRC—type 2 diabetes mellitus	1.34e-06	1.1e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	1.34e-06	1.1e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—INS—type 2 diabetes mellitus	1.34e-06	1.1e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	1.33e-06	1.1e-05	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—AKT1—type 2 diabetes mellitus	1.33e-06	1.09e-05	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—AKT1—type 2 diabetes mellitus	1.33e-06	1.09e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	1.33e-06	1.09e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	1.33e-06	1.09e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	1.32e-06	1.09e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PTGS2—type 2 diabetes mellitus	1.32e-06	1.08e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.31e-06	1.08e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—SRC—type 2 diabetes mellitus	1.3e-06	1.07e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—SRC—type 2 diabetes mellitus	1.3e-06	1.07e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—INS—type 2 diabetes mellitus	1.29e-06	1.06e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—INS—type 2 diabetes mellitus	1.29e-06	1.06e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.29e-06	1.06e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.29e-06	1.06e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.28e-06	1.06e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PTGS2—type 2 diabetes mellitus	1.28e-06	1.05e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—ALB—type 2 diabetes mellitus	1.27e-06	1.05e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.27e-06	1.05e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.27e-06	1.05e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.27e-06	1.05e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.25e-06	1.03e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.25e-06	1.03e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.25e-06	1.03e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.25e-06	1.03e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.25e-06	1.03e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.24e-06	1.02e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.24e-06	1.02e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PTGS2—type 2 diabetes mellitus	1.24e-06	1.02e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PTGS2—type 2 diabetes mellitus	1.24e-06	1.02e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—SRC—type 2 diabetes mellitus	1.24e-06	1.02e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	1.23e-06	1.01e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.23e-06	1.01e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.23e-06	1.01e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PIK3R1—type 2 diabetes mellitus	1.22e-06	1e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—NOS3—type 2 diabetes mellitus	1.22e-06	1e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—INS—type 2 diabetes mellitus	1.21e-06	9.95e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—SRC—type 2 diabetes mellitus	1.2e-06	9.84e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—SRC—type 2 diabetes mellitus	1.2e-06	9.84e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.19e-06	9.76e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.19e-06	9.76e-06	CbGpPWpGaD
Loperamide—CALM3—Immune System—EGFR—type 2 diabetes mellitus	1.17e-06	9.66e-06	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.17e-06	9.65e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.17e-06	9.63e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.17e-06	9.63e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	1.16e-06	9.56e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.14e-06	9.4e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	1.14e-06	9.4e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	1.14e-06	9.38e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	1.14e-06	9.36e-06	CbGpPWpGaD
Loperamide—CALM2—Immune System—EGFR—type 2 diabetes mellitus	1.14e-06	9.34e-06	CbGpPWpGaD
Loperamide—CALM1—Immune System—EGFR—type 2 diabetes mellitus	1.14e-06	9.34e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.13e-06	9.31e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.13e-06	9.31e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.13e-06	9.31e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.13e-06	9.31e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	1.12e-06	9.24e-06	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.12e-06	9.17e-06	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PTGS2—type 2 diabetes mellitus	1.11e-06	9.16e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	1.11e-06	9.12e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—TGFB1—type 2 diabetes mellitus	1.11e-06	9.09e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—RELA—type 2 diabetes mellitus	1.1e-06	9.06e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	1.09e-06	8.97e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—EGFR—type 2 diabetes mellitus	1.08e-06	8.91e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—TGFB1—type 2 diabetes mellitus	1.07e-06	8.8e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—TGFB1—type 2 diabetes mellitus	1.07e-06	8.8e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—RELA—type 2 diabetes mellitus	1.07e-06	8.77e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—RELA—type 2 diabetes mellitus	1.07e-06	8.77e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.06e-06	8.73e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	1.06e-06	8.73e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	1.06e-06	8.72e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—EGFR—type 2 diabetes mellitus	1.05e-06	8.62e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—EGFR—type 2 diabetes mellitus	1.05e-06	8.62e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	1.05e-06	8.6e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	1.04e-06	8.56e-06	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.03e-06	8.46e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	1.02e-06	8.38e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	1.02e-06	8.35e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	1e-06	8.22e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	1e-06	8.22e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CASP3—type 2 diabetes mellitus	9.94e-07	8.17e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	9.89e-07	8.14e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—IL6—type 2 diabetes mellitus	9.88e-07	8.12e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	9.77e-07	8.03e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	9.71e-07	7.98e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CASP3—type 2 diabetes mellitus	9.62e-07	7.91e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CASP3—type 2 diabetes mellitus	9.62e-07	7.91e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—IL6—type 2 diabetes mellitus	9.55e-07	7.86e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—IL6—type 2 diabetes mellitus	9.55e-07	7.86e-06	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IL6—type 2 diabetes mellitus	9.42e-07	7.75e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.39e-07	7.73e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	9.37e-07	7.71e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.29e-07	7.64e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	9.2e-07	7.56e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	9.15e-07	7.52e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.11e-07	7.49e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.09e-07	7.47e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.09e-07	7.47e-06	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL6—type 2 diabetes mellitus	9.02e-07	7.42e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	8.99e-07	7.39e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	8.99e-07	7.39e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	8.91e-07	7.32e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	8.81e-07	7.25e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	8.81e-07	7.25e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	8.76e-07	7.2e-06	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL6—type 2 diabetes mellitus	8.73e-07	7.18e-06	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL6—type 2 diabetes mellitus	8.73e-07	7.18e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	8.73e-07	7.18e-06	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.69e-07	7.15e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—SRC—type 2 diabetes mellitus	8.66e-07	7.12e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	8.63e-07	7.09e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.43e-07	6.94e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—SRC—type 2 diabetes mellitus	8.38e-07	6.89e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—SRC—type 2 diabetes mellitus	8.38e-07	6.89e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—IL6—type 2 diabetes mellitus	8.33e-07	6.85e-06	CbGpPWpGaD
Loperamide—CALM3—Immune System—AKT1—type 2 diabetes mellitus	8.32e-07	6.85e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.16e-07	6.71e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.16e-07	6.71e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—IL6—type 2 diabetes mellitus	8.06e-07	6.63e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—IL6—type 2 diabetes mellitus	8.06e-07	6.63e-06	CbGpPWpGaD
Loperamide—CALM2—Immune System—AKT1—type 2 diabetes mellitus	8.05e-07	6.62e-06	CbGpPWpGaD
Loperamide—CALM1—Immune System—AKT1—type 2 diabetes mellitus	8.05e-07	6.62e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.74e-07	6.37e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—AKT1—type 2 diabetes mellitus	7.69e-07	6.32e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	7.6e-07	6.25e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.59e-07	6.24e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.49e-07	6.16e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.49e-07	6.16e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	7.46e-07	6.13e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—AKT1—type 2 diabetes mellitus	7.43e-07	6.11e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—AKT1—type 2 diabetes mellitus	7.43e-07	6.11e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.34e-07	6.04e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.34e-07	6.04e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	6.83e-07	5.62e-06	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—AKT1—type 2 diabetes mellitus	6.61e-07	5.44e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	6.54e-07	5.38e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	6.54e-07	5.38e-06	CbGpPWpGaD
Loperamide—CALM3—Metabolism—AKT1—type 2 diabetes mellitus	6.44e-07	5.29e-06	CbGpPWpGaD
Loperamide—CALM1—Metabolism—AKT1—type 2 diabetes mellitus	6.23e-07	5.12e-06	CbGpPWpGaD
Loperamide—CALM2—Metabolism—AKT1—type 2 diabetes mellitus	6.23e-07	5.12e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	5.98e-07	4.92e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IL6—type 2 diabetes mellitus	5.83e-07	4.8e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IL6—type 2 diabetes mellitus	5.64e-07	4.64e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IL6—type 2 diabetes mellitus	5.64e-07	4.64e-06	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—AKT1—type 2 diabetes mellitus	5.6e-07	4.6e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.38e-07	4.43e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.21e-07	4.28e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.21e-07	4.28e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	4.88e-07	4.01e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	4.6e-07	3.78e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	3.01e-07	2.47e-06	CbGpPWpGaD
